

Our ref: IG/FOI/FOI.018.26

23 January 2026

Sent via email to: [REDACTED]

Dear [REDACTED]

Request under the Freedom of Information Act 2000

I write further to your request for information which was received on 12 January 2026, to confirm, in accordance with S.1(1)(a) of the Freedom of Information Act 2000, that Powys Teaching Health Board (PTHB) does not hold the information that you require. For ease of reference your request is set out below and the Health Board's response follows.

Your Freedom of Information (FOI) Request:

I am writing to you under the Freedom of Information Act to request the following information:

Q1. How many patients who have a current diagnosis of Multiple Sclerosis received treatment in the last six months with any of the following treatment regimens (July 2025 – December 2025)?

- Ocrevus (ocrelizumab) IV (300mg/30ml)
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
- Kesimpta (ofatumumab)
- Briumvi (ublituximab)
- Mavenclad (cladribine)
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
- Natalizumab (Tysabri and Tyruko)

Q1a. Of the patients identified in question one, how many patients received the same treatment in the previous six-month period? (i.e. How many of the same patients received treatment with each treatment regimen in January 2025 to June 2025 AND July 2025 – December 2025?)

- Ocrevus (ocrelizumab) IV (300mg/30ml)
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
- Kesimpta (ofatumumab)
- Briumvi (ublituximab)
- Mavenclad (cladribine)
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
- Natalizumab (Tysabri and Tyruko)

Q2. How many patients have received a new diagnosis for Multiple Sclerosis in the latest six-month period (July 2025 – December 2025)?

Q2a. Of the patients identified in question two, how many of these patients have received any of the following treatment regimens as their first treatment following their Multiple Sclerosis diagnosis?

- Ocrevus (ocrelizumab) IV (300mg/30ml)
- Ocrevus (ocrelizumab) Subcutaneous (920mg/23ml)
- Kesimpta (ofatumumab)
- Briumvi (ublituximab)
- Mavenclad (cladribine)
- Dimethyl Fumarate (Tecfidera + Dimethyl Fumarate generic)
- Natalizumab (Tysabri and Tyruko)

Powys Response:

Q1 – Q2a. I can confirm that Powys Teaching Health Board (PTHB) does not initiate treatment with any of the medicines listed; patients are treated by providers outside of Powys. PTHB commissions services from a number of Welsh health boards and English provider organisations.

PTHB does not have a neurology consultant and patients with suspected Multiple Sclerosis will be referred to neighbouring District General Hospitals.

Due to the complex nature of PTHB’s commissioning arrangements, not all of our providers indicate the indication for use for each episode of care where these drugs are used. For this reason, PTHB does not hold the data relating to your request, however, the health board is working closely with providers to ensure that this information can be provided in the future. We therefore recommend that you approach our providers for this information directly:

Please note that all providers may not necessarily offer services that fall within the definition in your request.

Health Trust/Organisation	FOI Contact Details
Gloucestershire Hospitals NHS Foundation Trust	ghn-tr.foi@nhs.net
Midlands Partnership University NHS Foundation Trust	FOI@mpft.nhs.uk
The Robert Jones Agnes Hunt Orthopaedic Hospital NHS Foundation Trust	rjah.foi@nhs.net
Sandwell and West Birmingham NHS Trust	swb-tr.SWBH-GM-FOIRequests@nhs.net
The Shrewsbury and Telford Hospital NHS Trust	sath.foi@nhs.net
The Royal Wolverhampton NHS Trust	rwh-tr.foi@nhs.net
Worcestershire Acute Hospitals NHS Trust	wah-tr.FOI@nhs.net
Wye Valley NHS Trust	Freedom.Information@wvt.nhs.uk

Health Board/Organisation	FOI Contact Details
Aneurin Bevan University Health Board	FOI.ABB@wales.nhs.uk
Betsi Cadwaladr University Health Board	bcu.foi@wales.nhs.uk

Cardiff & Vale University Health Board	FOI.Requests@wales.nhs.uk
Cwm Taf Morgannwg University Health Board	CTM.FreedomOfInformation@wales.nhs.uk
Hywel Dda University Health Board	FOI.hyweldda@wales.nhs.uk
Swansea Bay University Health Board	FOIA.Requests@wales.nhs.uk
Velindre University NHS Trust	Foi.vunhst@wales.nhs.uk

If you have queries or any concerns, contact details are given at the top of the letter. Please remember to quote the reference number above in any future communications. If you are dissatisfied with the handling or response to your request and wish to ask for a review of this, please contact us and we will arrange for this to be done.

Further information is available from the Information Commissioner's Office who can be contacted at:

Address: Information Commissioner's Office (Wales), 2nd Floor, Churchill House, Churchill Way, Cardiff, CF10 2HH.

Telephone: 0330 414 6421

Complaints Portal: www.ico.org.uk/foicomplaints

Web site: <https://ico.org.uk/>


Re-use of Public Sector Information

All information supplied by the Health Board in answering a request for information (RFI) under the Freedom of Information Act 2000 will be subject to the terms of the Re-use of Public Sector Information Regulations 2015.

Under the terms of the Regulations, the Health Board will licence the re-use of any or all information supplied if being used in a form and for the purpose other than which it was originally supplied. This license for re-use will be in line with the requirements of the Regulations and the licensing terms and fees as laid down by the Office of Public Sector Information (OPSI). Most licenses will be free; however, the Health Board reserves the right, in certain circumstances to charge a fee for the re-use of some information which it deems to be of commercial value.

Further information including a sample license terms and fees can be found at Open Government Licence.

Yours sincerely



Kate Wright
Executive Medical Director

Rydym yn croesawu derbyn gohebiaeth yng Nghymraeg. Byddwn yn ateb y fath ohebiaeth yng Nghymraeg ac ni fydd hyn yn arwain at oedi.

We welcome receiving correspondence in Welsh. We will reply to such correspondence in Welsh and this will not lead to a delay.